New biomarkers play a key role in individualised tumour therapy. They are important indicators for pathological processes in the body and for the use of adequate cancer drugs. In our European Hospital interview Professor Celso A Reis, from the Institute of Molecular Pathology and Immunology of the University of Porto (IPATIMUP*) in Portugal, discussed the current state of clinical use of…
More than 2 million over the world suffer from Multiple sclerosis (MS). It attacks the central nervous system and eventually renders most patients disabled. Although there is currently no cure, a breakthrough finding from a Tel Aviv University scientist and physician may lead to earlier diagnosis, more effective intervention, and perhaps even a cure for the autoimmune disease.
To mark the first European Parkinson’s Action Day on April 12th, the European Parkinson’s Disease Association (EPDA) announced the launch of a major new investigation into the care of people with Parkinson’s across 36 European countries. Parkinson’s disease is the second most common progressive neurodegenerative condition which affects people from all around the world.
A special feature of this year’s scientific program at ECR 2010 was a joint session organized by the European Association for Nuclear Medicine with the European Society of Radiology. Two speakers representing the EANM took the podium to review developments in nuclear medicine and to challenge colleagues on specific applications.
Since June 2009, the focus of research in the European Network for Cell Imaging and Tracking Expertise (ENCITE) has been on finding biomarkers to aid cell transplantation. Funded with €11 million from the European Commission (EC), this major project that runs until 2013, involves 10 countries. Their work is coordinated by the European Institute for Biomedical Imaging Research (EIBIR) network,…
Molecular imaging, the discipline that unites molecular biology and in vivo imaging technologies to assess biological activity in the body, promises to open up ‘…an entire new universe,’ declared Dr Ralph Weissleder, of the Centre for Molecular Imaging Research at Massachusetts General Hospital, USA, in the journal Radiology. That was just one decade ago. And he was right. It has indeed…
While lower intelligence scores have been associated with a raised risk of cardiovascular disease, no study has so far compared the relative strength of this association with other established risk factors such as obesity, smoking and high blood pressure. Now, a large study has found that lower intelligence scores were associated with higher rates of cardiovascular disease and total mortality at…
Entrepreneur Dr Gunter Pollanz was a central figure in the build-up of charter flights to Israel and in the foundation of MAOF Airlines in Tel Aviv. Later, he also developed important export structures from Israel to Europe. However, in 1997 his life took a dramatic turn when he was diagnosed with lymphoma. Prognosis: Although 54 years old he faced just three more months of life. Today, Dr…
Scientists are closer to discovering why some people respond to breast cancer radiotherapy better than others, according to Breast Cancer Campaign. Dr Laura Smith, at the Leeds Institute of Molecular Medicine, University of Leeds, has been awarded a pilot grant by Breast Cancer Campaign, to study why some types of breast cancers are difficult to destroy with radiotherapy.
For many years we have heard about personalised cancer treatments, understood each cancer patient is different and that 'one size fits all' treatments are not appropriate. We have been told that early diagnosis is the key to successful treatment and that no two patients have the same genetic or biological profile.
This year's AACC, held in conjunction with the Canadian Society for Clinical Chemists, and the Annual Meeting of the American Society for Clinical Laboratory Science, featured around 200 educational sessions and drew in over 18,000 delegates and exhibitors from almost 100 countries.
"In-vitro veritas", the slogan of the 18th European Congress of Clinical Chemistry and Laboratory Medicine, which took place in June, underlined the significance of in vitro diagnostics for healthcare, and the presentations by 90 speakers, in 32 scientific sessions and 29 industry sponsored workshops, demonstrated the rich variety of developments.
The technology firm NCR Corporation, which specialises in automated teller machines, self-checkouts and other self- and assisted-service solutions, announced in April that King's College Hospital NHS Foundation Trust in London has chosen to install the firm's new patient automated arrival system NCR MediKiosk. This autumn, 50 MediKiosks will be deployed in the dermatology, haematology,…
President Barack Obama has made e-prescribing an element of his plan to improve the US healthcare system
Biomarkers are biochemical features or facets that can be used to measure the progress of disease or the effects of treatment.
Working in partnership to integrate diagnostic imaging, laboratory diagnostics and IT, the Hospital Clinic Barcelona and Siemens Healthcare aim to develop innovative systems to prevent, treat and follow-up for various pathologies.
Coronary heart disease (CHD) symptoms, presented in the context of a stressful life event, were identified as psychogenic when presented by women and organic when presented by men, which could help explain why there is often a delay in the assessment of women with CHD, according to research presented at the 20th annual Transcatheter Cardiovascular Therapeutics (TCT) conference.
Germans want a different healthcare system. 93% want individualised services — and they are prepared to pay for them, according to a study relating to the strategies of providers in Germany's healthcare system and their acceptance by the public.
The American Association for Clinical Chemistry (AACC) and the Australasian Association of Clinical Biochemists (AACB) are joining together for the second time for a conference on major changes facing laboratorians in coming years, under the banner Laboratory Medicine - Into the Future.
The US Agency for Healthcare Research and Quality (AHRQ) will fund a new project to develop four computer-based decision-tools that will help clinicians and patients answering questions like: When to use genetic tests? How to deal with the results? Or which treatment could be the best?
Moving personalized medicine from promise to practice. Siemens Healthcare announces the early study findings of a new imaging biomarker for hypoxic tumors. This clinically problematic cells tend to be less responsive to standard treatment regimens. A probe that measures hypoxia could prove quite a useful tool for oncologists.
The Old Dominion University in Virginia and Regensburg University Medical Center in Germany are jointly organizing an international conference to discuss recent advances and strategic needs in personalised healthcare (pHealth) care and to foster collaboration between industry and academia.
The seca 959, a chair scale, has been designed by seca gmbh & co. kg, Hamburg, Germany, with input from experts, to accommodate patients with mobility or other problems. It is not only easy for patients and nurses to use, but, as the firm explains, ` practically eliminates body contact, which patients of Islamic faith in particular find unpleasant and try to avoid.´
More than 250,000 women under the age of forty are living with the disease in the US and 11,000 will be diagnosed in the next year. Even so, young women are underrepresented in many research studies and treatments, according to genomic expert Simon Chin.
The future of the in vitro diagnostics (IVD) market looks promising. According to a new analysis from Frost & Sullivan, Western European IVD Market is estimated to reach $12.65 billion in 2014. The reason: Diseases depending on an aging population, such as infections, hike the demand for automated diagnostic tools.